Journal
BLOOD CANCER DISCOVERY
Volume 3, Issue 2, Pages 95-102Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2643-3230.BCD-21-0222
Keywords
-
Categories
Funding
- Leukemia & Lymphoma Society [IRV-BC0003-22]
- Fast Grants
- Stanford ChEM-H Innovative Medicines Accelerator program
- NIH career development award [K08CA252637]
- NIH [R35CA19735306]
Ask authors/readers for more resources
In patients with lymphoma, the time since anti-CD20 treatment is an important predictor of neutralizing antibody response to COVID-19 vaccination. Comparing patients who received anti-CD20 treatment before or after vaccination, we demonstrate that vaccinating first can generate a durable antibody response that persists during anti-CD20-containing treatment.
To obtain a deeper understanding of poor responses to COVID-19 vaccination in patients with lymphoma. we assessed blocking antibodies, total anti-spike IgG, and spike-specific memory B cells in the peripheral blood of 126 patients with lymphoma and 20 age-matched healthy controls 1 and 4 months after COVID-19 vaccination. Fifty-five percent of patients developed blocking antibodies postvaccination. compared with 100% of controls. When evaluating patients last treated from days to nearly 18 years prior to vaccination, time since last anti-CD20 was a significant independent predictor of vaccine response. None of 31 patients who had received anti-CD20 treatment within 6 months prior to vaccination developed blocking antibodies. In contrast, patients who initiated anti-CD20 treatment shortly after achieving a vaccine-induced antibody response tended to retain that response during treatment, suggesting a policy of immunizing prior to treatment whenever possible. SIGNIFICANCE: In a large cohort of patients with B-cell lymphoma, time since anti-CD20 treatment was an independent predictor of neutralizing antibody response to COVID-19 vaccination. Comparing patients who received anti-CD20 treatment before or after vaccination, we demonstrate that vaccinating first can generate an antibody response that endures through anti-CD20-containing treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available